Nxera Pharma Valuation Multiples

Nxera Pharma is valued at $700M as of October 2026, a 3.8x revenue multiple. In the last 12 months, Nxera Pharma revenue was $245M and Nxera Pharma EBITDA was $45M.

Nxera Pharma Overview

About Nxera Pharma

Nxera Pharma is a biopharmaceutical company founded in 1990 and based in Japan. OPF1 is a fund launched in September 2023 with JIC VGI as its General Partner, whose strategy is to provide funding to direct secondary deals and listed startups. OPF1 is one ofthe JIC's initiatives included in the government's "Startup Development Five-Year Plan". The company serves business and institutional customers through products and services in the biopharmaceutical market. Its commercial model is built primarily on technology licensing and product sales, reflecting the way customers obtain and use its offering. JIC Venture Growth Investments classifies the business in its After Market portfolio and records December 2023 for the company. The company maintains its operating website at www.nxera.life, while JIC VGI's portfolio materials preserve the public record of the investment relationship.


Founded

1990

HQ

Japan

Employees

443

Website

nxera.life

Financials (LTM)

Revenue: $245M
EBITDA: $45M

EV

$931M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Nxera Pharma Financials

Nxera Pharma reported last 12-month revenue of $245M and EBITDA of $45M.

In the same LTM period, Nxera Pharma generated $45M in EBITDA and $4M in net income.

Revenue (LTM)


Nxera Pharma P&L

In the most recent fiscal year, Nxera Pharma reported revenue of $187M and EBITDA of ($26M).

Nxera Pharma is unprofitable as of last fiscal year, with gross margin of 72%, EBITDA margin of (14%), and net margin of (42%).

See analyst estimates for Nxera Pharma
LTMLast FY202320242025202620272028
Revenue$245M$187M$80M$181M$187M
Gross Profit-$135M$61M$133M$135M
Gross Margin-72%76%74%72%
EBITDA$45M($26M)($36M)$659K($26M)
EBITDA Margin18%(14%)(45%)0%(14%)
EBIT Margin16%(29%)(75%)(19%)(29%)
Net Profit$4M($79M)($45M)($30M)($79M)
Net Margin1%(42%)(56%)(17%)(42%)
Net Debt-$212M---

Financial data powered by Morningstar, Inc.

Nxera Pharma Stock Performance

Nxera Pharma has current market cap of $700M, and enterprise value of $931M.

Market Cap Evolution


Nxera Pharma's stock price is $7.66.

Nxera Pharma share price decreased by 3.5% in the last 30 days, and increased by 31.7% in the last year.

Nxera Pharma has an EPS (earnings per share) of $-0.87.

See more trading valuation data for Nxera Pharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$931M$700M-3.5%-3.5%38.4%31.7%$-0.87

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Nxera Pharma Valuation Multiples

Nxera Pharma trades at 3.8x EV/Revenue multiple, and 20.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Nxera Pharma

EV / Revenue (LTM)


Nxera Pharma Financial Valuation Multiples

As of October 10, 2026, Nxera Pharma has market cap of $700M and EV of $931M.

Nxera Pharma has a P/E ratio of 191.8x.

LTMLast FY202320242025202620272028
EV/Revenue3.8x5.0x11.6x5.1x5.0x
EV/EBITDA20.7x(36.0x)(26.0x)n/m(36.0x)
EV/EBIT23.9x(17.4x)(15.6x)(27.4x)(17.4x)
EV/Gross Profit-6.9x15.4x7.0x6.9x
P/E191.8x(8.8x)(15.5x)(23.0x)(8.8x)
EV/FCF-(44.8x)(24.2x)(16.0x)(44.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Nxera Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Nxera Pharma Margins & Growth Rates

Nxera Pharma grew revenue by 39% but EBITDA decreased by 358% in the last fiscal year.

In the most recent fiscal year, Nxera Pharma reported gross margin of 72%, EBITDA margin of (14%), and net margin of (42%).

See estimated margins and future growth rates for Nxera Pharma

Nxera Pharma Margins

Last FY202420252026202720282029
Gross Margin72%74%72%83%
EBITDA Margin(14%)0%(14%)26%
EBIT Margin(29%)(19%)(29%)20%
Net Margin(42%)(17%)(42%)11%
FCF Margin(11%)(32%)(11%)21%

Nxera Pharma Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth39%126%3%39%
Gross Profit Growth59%120%2%59%
EBITDA Growth(358%)(102%)(4026%)(358%)
EBIT Growth(195%)(43%)57%(195%)
Net Profit Growth(136%)(33%)161%(136%)
FCF Growth(359%)51%(64%)(359%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Nxera Pharma Operational KPIs

Nxera Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.

Nxera Pharma's Rule of 40 is 65% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Nxera Pharma's Rule of X is 123% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Nxera Pharma
LTMLast FY202320242025202620272028
Rule of 4029%65%---
Bessemer Rule of X46%123%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.4M---
G&A Expenses to Revenue-51%78%56%51%
R&D Expenses to Revenue33%49%79%41%49%
Opex to Revenue-101%150%92%101%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Nxera Pharma Competitors

Nxera Pharma competitors include 4D Molecular Therapeutics, SK Chemicals, Sanofi India, Olema Pharmaceuticals, WAVE Life Sciences, Gyre Therapeutics, Pharming, Supriya Lifescience, Design Therapeutics and Collegium Pharmaceutical.

Most Nxera Pharma public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
4D Molecular Therapeutics$85M($152M)4.5x12.8x(2.5x)(1.4x)
SK Chemicals$1.8B$172M1.0x0.9x10.5x9.7x
Sanofi India$189M$49M3.6x3.4x13.9x12.0x
Olema Pharmaceuticals-($178M)--(1.3x)(1.0x)
WAVE Life Sciences$43M($196M)5.5x5.0x(1.2x)(1.1x)
Gyre Therapeutics$117M$15M6.0x6.3x46.2x(16.4x)
Pharming$376M$34M1.7x1.7x19.0x23.7x
Supriya Lifescience$83M$31M8.6x7.5x23.0x21.6x

This data is available for Pro users. Sign up to see all Nxera Pharma competitors and their valuation data.

Start Free Trial

Nxera Pharma VC Funding History

Before going public, Nxera Pharma raised funding across 1 round.


Nxera Pharma Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Dec-23Strategic investmentJIC--On December 15, 2023, JIC announced an equity investment in Nxera Pharma through JICVGI Opportunity Fund No. 1. The investing entity was JIC Venture Growth Investments, the JIC group manager responsible for direct venture, growth and listed-startup transactions, so the investment is attributed to the JIC investment house. OPF1 is a fund launched in September 2023 with JIC VGI as its General Partner, whose strategy is to provide funding to direct secondary deals and listed startups. OPF1 is one ofthe JIC's initiatives included in the government's "Startup Development Five-Year Plan". JIC VGI described the policy and investment rationale as an effort to support the development and commercialization of medical technologies and strengthen links between Japanese life-sciences research, clinical development and global markets. The transaction established JIC's direct investment relationship with the company and placed it within JIC VGI's After Market portfolio. JIC VGI said its capital and operating support would help Nxera Pharma advance product development, commercialization, hiring, partnerships or market expansion in line with the company-specific plans described in the announcement. The official announcement identifies a share acquisition or subscription by the JIC-managed vehicle, giving the fund an equity position tied to the company's stated development and commercialization plan.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Nxera Pharma

When was Nxera Pharma founded?Nxera Pharma was founded in 1990.
Where is Nxera Pharma headquartered?Nxera Pharma is headquartered in Japan.
How many employees does Nxera Pharma have?As of today, Nxera Pharma has over 443 employees.
Who is the CEO of Nxera Pharma?Nxera Pharma's CEO is Christopher Cargill.
Is Nxera Pharma publicly listed?Yes, Nxera Pharma is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of Nxera Pharma?Nxera Pharma trades under 4565 ticker.
When did Nxera Pharma go public?Nxera Pharma went public in 2004.
Who are competitors of Nxera Pharma?Nxera Pharma main competitors include 4D Molecular Therapeutics, SK Chemicals, Sanofi India, Olema Pharmaceuticals, WAVE Life Sciences, Gyre Therapeutics, Pharming, Supriya Lifescience, Design Therapeutics, Collegium Pharmaceutical.
What is the current market cap of Nxera Pharma?Nxera Pharma's current market cap is $700M.
What is the current revenue of Nxera Pharma?Nxera Pharma's last 12 months revenue is $245M.
What is the current revenue growth of Nxera Pharma?Nxera Pharma revenue growth (NTM/LTM) is 11%.
What is the current EV/Revenue multiple of Nxera Pharma?Current revenue multiple of Nxera Pharma is 3.8x.
What is the current EBITDA of Nxera Pharma?Nxera Pharma's last 12 months EBITDA is $45M.
What is Nxera Pharma's EBITDA margin?Nxera Pharma's last 12 months EBITDA margin is 18%.
What is the current EV/EBITDA multiple of Nxera Pharma?Current EBITDA multiple of Nxera Pharma is 20.7x.
How many companies Nxera Pharma has acquired to date?Nxera Pharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Nxera Pharma has invested to date?Nxera Pharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Nxera Pharma

Lists including Nxera Pharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial